Kaynar2018 Medscape PDF

19/10/2019 https://emedicine.medscape.
com/article/167981-print
emedicine.medscape.com
Respiratory Failure
Updated: Jul 25, 2018
Author: Ata Murat Kaynar, MD; Chief Editor: Michael R Pinsky, MD, CM, Dr(HC), FCCP, FAPS, MCCM
Overview
Background
Respiratory failure is a syndrome in which the respiratory system fails in one or both of its gas exchange functions:
oxygenation and carbon dioxide elimination. In practice, it may be classified as either hypoxemic or hypercapnic.
Hypoxemic respiratory failure (type I) is characterized by an arterial oxygen tension (PaO2) lower than 60 mm Hg with a
normal or low arterial carbon dioxide tension (PaCO2). This is the most common form of respiratory failure, and it can be
associated with virtually all acute diseases of the lung, which generally involve fluid filling or collapse of alveolar units. Some
examples of type I respiratory failure are cardiogenic or noncardiogenic pulmonary edema, pneumonia, and pulmonary
hemorrhage.
Hypercapnic respiratory failure (type II) is characterized by a PaCO2 higher than 50 mm Hg. Hypoxemia is common in
patients with hypercapnic respiratory failure who are breathing room air. The pH depends on the level of bicarbonate, which,
in turn, is dependent on the duration of hypercapnia. Common etiologies include drug overdose, neuromuscular disease,
chest wall abnormalities, and severe airway disorders (eg, asthma and chronic obstructive pulmonary disease [COPD]).
Respiratory failure may be further classified as either acute or chronic. Although acute respiratory failure is characterized by
life-threatening derangements in arterial blood gases and acid-base status, the manifestations of chronic respiratory failure
are less dramatic and may not be as readily apparent.
Acute hypercapnic respiratory failure develops over minutes to hours; therefore, pH is less than 7.3. Chronic respiratory
failure develops over several days or longer, allowing time for renal compensation and an increase in bicarbonate
concentration. Therefore, the pH usually is only slightly decreased.
The distinction between acute and chronic hypoxemic respiratory failure cannot readily be made on the basis of arterial
blood gases. The clinical markers of chronic hypoxemia, such as polycythemia or cor pulmonale, suggest a long-standing
disorder.
Arterial blood gases should be evaluated in all patients who are seriously ill or in whom respiratory failure is suspected.
Chest radiography is essential. Echocardiography is not routine but is sometimes useful. Pulmonary functions tests (PFTs)
may be helpful. Electrocardiography (ECG) should be performed to assess the possibility of a cardiovascular cause of
respiratory failure; it also may detect dysrhythmias resulting from severe hypoxemia or acidosis. Right-sided heart
catheterization is controversial (see Workup).
Hypoxemia is the major immediate threat to organ function. After the patient’s hypoxemia is corrected and the ventilatory
and hemodynamic status have stabilized, every attempt should be made to identify and correct the underlying
pathophysiologic process that led to respiratory failure in the first place. The specific treatment depends on the etiology of
respiratory failure (see Treatment).
For patient education resources, see the Lung and Airway Center, as well as Acute Respiratory Distress Syndrome.
Pathophysiology
Respiratory failure can arise from an abnormality in any of the components of the respiratory system, including the airways,
alveoli, central nervous system (CNS), peripheral nervous system, respiratory muscles, and chest wall. Patients who have
hypoperfusion secondary to cardiogenic, hypovolemic, or septic shock often present with respiratory failure.
https://emedicine.medscape.com/article/167981-print 1/29
19/10/2019 https://emedicine.medscape.com/article/167981-print
Ventilatory capacity is the maximal spontaneous ventilation that can be maintained without development of respiratory
muscle fatigue. Ventilatory demand is the spontaneous minute ventilation that results in a stable PaCO2.
Normally, ventilatory capacity greatly exceeds ventilatory demand. Respiratory failure may result from either a reduction in
ventilatory capacity or an increase in ventilatory demand (or both). Ventilatory capacity can be decreased by a disease
process involving any of the functional components of the respiratory system and its controller. Ventilatory demand is
augmented by an increase in minute ventilation and/or an increase in the work of breathing.
Respiratory physiology
The act of respiration engages the following three processes:
Transfer of oxygen across the alveolus
Transport of oxygen to the tissues
Removal of carbon dioxide from blood into the alveolus and then into the environment
Respiratory failure may occur from malfunctioning of any of these processes. In order to understand the pathophysiologic
basis of acute respiratory failure, an understanding of pulmonary gas exchange is essential.
Gas exchange
Respiration primarily occurs at the alveolar capillary units of the lungs, where exchange of oxygen and carbon dioxide
between alveolar gas and blood takes place. After diffusing into the blood, the oxygen molecules reversibly bind to the
hemoglobin. Each molecule of hemoglobin contains 4 sites for combination with molecular oxygen; 1 g of hemoglobin
combines with a maximum of 1.36 mL of oxygen.
The quantity of oxygen combined with hemoglobin depends on the level of blood PaO2. This relationship, expressed as the
oxygen hemoglobin dissociation curve, is not linear but has a sigmoid-shaped curve with a steep slope between a PaO2 of
10 and 50 mm Hg and a flat portion above a PaO2 of 70 mm Hg.
The carbon dioxide is transported in 3 main forms: (1) in simple solution, (2) as bicarbonate, and (3) combined with protein
of hemoglobin as a carbamino compound.
During ideal gas exchange, blood flow and ventilation would perfectly match each other, resulting in no alveolar-arterial
oxygen tension (PO2) gradient. However, even in normal lungs, not all alveoli are ventilated and perfused perfectly. For a
given perfusion, some alveoli are underventilated, while others are overventilated. Similarly, for known alveolar ventilation,
some units are underperfused, while others are overperfused.
The optimally ventilated alveoli that are not perfused well have a large ventilation-to-perfusion ratio (V/Q) and are called
high-V/Q units (which act like dead space). Alveoli that are optimally perfused but not adequately ventilated are called low-
V/Q units (which act like a shunt).
Alveolar ventilation
At steady state, the rate of carbon dioxide production by the tissues is constant and equals the rate of carbon dioxide
elimination by the lung. This relation is expressed by the following equation:
VA = K × VCO2/ PaCO2
where K is a constant (0.863), VA is alveolar ventilation, and VCO2 is carbon dioxide ventilation. This relation determines
whether the alveolar ventilation is adequate for metabolic needs of the body.
The efficiency of lungs at carrying out of respiration can be further evaluated by measuring the alveolar-arterial PO2
gradient. This difference is calculated by the following equation:
PAO2 = FiO2 × (PB – PH2 O) – PACO2/R
where PA O2 is alveolar PO2, FiO2 is fractional concentration of oxygen in inspired gas, PB is barometric pressure, PH2O
is water vapor pressure at 37°C, PACO2 is alveolar PCO2 (assumed to be equal to PaCO2), and R is respiratory exchange
ratio. R depends on oxygen consumption and carbon dioxide production. At rest, the ratio of VCO2 to oxygen ventilation
(VO2) is approximately 0.8.
Even normal lungs have some degree of V/Q mismatching and a small quantity of right-to-left shunt, with PAO2 slightly
higher than PaO2. However, an increase in the alveolar-arterial PO2 gradient above 15-20 mm Hg indicates pulmonary
disease as the cause of hypoxemia.
Hypoxemic respiratory failure
The pathophysiologic mechanisms that account for the hypoxemia observed in a wide variety of diseases are V/Q mismatch
and shunt. These 2 mechanisms lead to widening of the alveolar-arterial PO2 gradient, which normally is less than 15 mm
Hg. They can be differentiated by assessing the response to oxygen supplementation or calculating the shunt fraction after
inhalation of 100% oxygen. In most patients with hypoxemic respiratory failure, these 2 mechanisms coexist.
V/Q mismatch
V/Q mismatch is the most common cause of hypoxemia. Alveolar units may vary from low-V/Q to high-V/Q in the presence
of a disease process. The low-V/Q units contribute to hypoxemia and hypercapnia, whereas the high-V/Q units waste
ventilation but do not affect gas exchange unless the abnormality is quite severe.
The low V/Q ratio may occur either from a decrease in ventilation secondary to airway or interstitial lung disease or from
overperfusion in the presence of normal ventilation. The overperfusion may occur in case of pulmonary embolism, where the
blood is diverted to normally ventilated units from regions of lungs that have blood flow obstruction secondary to embolism.
Administration of 100% oxygen eliminates all of the low-V/Q units, thus leading to correction of hypoxemia. Hypoxemia
increases minute ventilation by chemoreceptor stimulation, but the PaCO2 generally is not affected.
Shunt
Shunt is defined as the persistence of hypoxemia despite 100% oxygen inhalation. The deoxygenated blood (mixed venous
blood) bypasses the ventilated alveoli and mixes with oxygenated blood that has flowed through the ventilated alveoli,
consequently leading to a reduction in arterial blood content. The shunt is calculated by the following equation:
QS/QT = (CCO2 – CaO2)/CCO2 – CvO2)
where QS/QT is the shunt fraction, CCO2 is capillary oxygen content (calculated from ideal PAO2), CaO2 is arterial oxygen
content (derived from PaO2 by using the oxygen dissociation curve), and CvO2 is mixed venous oxygen content (assumed
or measured by drawing mixed venous blood from a pulmonary arterial catheter).
Anatomic shunt exists in normal lungs because of the bronchial and thebesian circulations, which account for 2-3% of shunt.
A normal right-to-left shunt may occur from atrial septal defect, ventricular septal defect, patent ductus arteriosus, or
arteriovenous malformation in the lung.
Shunt as a cause of hypoxemia is observed primarily in pneumonia, atelectasis, and severe pulmonary edema of either
cardiac or noncardiac origin. Hypercapnia generally does not develop unless the shunt is excessive (> 60%). Compared
with V/Q mismatch, hypoxemia produced by shunt is difficult to correct by means of oxygen administration.
Hypercapnic respiratory failure
At a constant rate of carbon dioxide production, PaCO2 is determined by the level of alveolar ventilation according to the
following equation (a restatement of the equation given above for alveolar ventilation):
PaCO2 = VCO2 × K/VA
where K is a constant (0.863). The relation between PaCO2 and alveolar ventilation is hyperbolic. As ventilation decreases
below 4-6 L/min, PaCO2 rises precipitously. A decrease in alveolar ventilation can result from a reduction in overall (minute)
ventilation or an increase in the proportion of dead space ventilation. A reduction in minute ventilation is observed primarily
in the setting of neuromuscular disorders and CNS depression. In pure hypercapnic respiratory failure, the hypoxemia is
easily corrected with oxygen therapy.
Hypoventilation is an uncommon cause of respiratory failure and usually occurs from depression of the CNS from drugs or
neuromuscular diseases affecting respiratory muscles. Hypoventilation is characterized by hypercapnia and hypoxemia.
Hypoventilation can be differentiated from other causes of hypoxemia by the presence of a normal alveolar-arterial PO2
gradient.
Etiology
These diseases can be grouped according to the primary abnormality and the individual components of the respiratory
system (eg, CNS, peripheral nervous system, respiratory muscles, chest wall, airways, and alveoli).
A variety of pharmacologic, structural, and metabolic disorders of the CNS are characterized by depression of the neural
drive to breathe. This may lead to acute or chronic hypoventilation and hypercapnia. Examples include tumors or vascular
abnormalities involving the brain stem, an overdose of a narcotic or sedative, and metabolic disorders such as myxedema or
chronic metabolic alkalosis.
Disorders of the peripheral nervous system, respiratory muscles, and chest wall lead to an inability to maintain a level of
minute ventilation appropriate for the rate of carbon dioxide production. Concomitant hypoxemia and hypercapnia occur.
Examples include Guillain-Barré syndrome, muscular dystrophy, myasthenia gravis, severe kyphoscoliosis, and morbid
obesity.
Severe airway obstruction is a common cause of acute and chronic hypercapnia. Examples of upper-airway disorders are
acute epiglottitis and tumors involving the trachea; lower-airway disorders include COPD, asthma, and cystic fibrosis.
Diseases of the alveoli are characterized by diffuse alveolar filling, frequently resulting in hypoxemic respiratory failure,
although hypercapnia may complicate the clinical picture. Common examples are cardiogenic and noncardiogenic
pulmonary edema, aspiration pneumonia, or extensive pulmonary hemorrhage. These disorders are associated with
intrapulmonary shunt and an increased work of breathing.
Common causes of type I (hypoxemic) respiratory failure include the following:
COPD
Pneumonia
Pulmonary edema
Pulmonary fibrosis
Asthma
Pneumothorax
Pulmonary embolism
Pulmonary arterial hypertension
Pneumoconiosis
Granulomatous lung diseases
Cyanotic congenital heart disease
Bronchiectasis
Acute respiratory distress syndrome (ARDS)
Fat embolism syndrome
Kyphoscoliosis
Obesity
Common causes of type II (hypercapnic) respiratory failure include the following:
COPD
Severe asthma
Drug overdose
Poisonings
Myasthenia gravis
Polyneuropathy
Poliomyelitis
Primary muscle disorders
Porphyria
Cervical cordotomy
Head and cervical cord injury
Primary alveolar hypoventilation
Obesity-hypoventilation syndrome
Pulmonary edema
ARDS
Myxedema
Tetanus
Epidemiology
Respiratory failure is a syndrome rather than a single disease process, and the overall frequency of respiratory failure is not
well known. The estimates for individual diseases mentioned in this article can be found in the Medscape Reference articles
specific to each disease.
The relationship between acute respiratory failure and race is still debated. A study by Khan et al suggested that no
differences in mortality exist in patients of Asian and Native Indian descent with acute critical illness after adjusting for
differences in case mix.[1] Moss and Mannino reported worse outcome for African Americans with ARDS than for whites
after adjustment for case mix.[2] Future prospective association studies should yield a better knowledge of the impact of
race on the outcome of respiratory failure.
Prognosis
The mortality associated with respiratory failure varies according to the etiology. For ARDS, mortality is approximately 40-
45%; this figure has not changed significantly over the years.[3, 4] Younger patients (< 60 y) have better survival rates than
older patients. Approximately two thirds of patients who survive an episode of ARDS manifest some impairment of
pulmonary function 1 or more years after recovery.
Significant mortality also occurs in patients admitted with hypercapnic respiratory failure. This is because these patients
have a chronic respiratory disorder and other comorbidities such as cardiopulmonary, renal, hepatic, or neurologic disease.
These patients also may have poor nutritional status.
For patients with COPD and acute respiratory failure, the overall mortality has declined from approximately 26% to 10%.
Acute exacerbation of COPD carries a mortality of approximately 30%. The mortality rates for other causative disease
processes have not been well described.
A study by Noveanu et al suggests a strong association between the preadmission use of beta-blockers and in-hospital and
1-year mortality among patients with acute respiratory failure.[5] Although cessation exacerbates the mortality, predischarge
initiation of beta-blockers is also associated with an improved 1-year mortality.
Presentation
History
The diagnosis of acute or chronic respiratory failure begins with clinical suspicion of its presence. Confirmation of the
diagnosis is based on arterial blood gas analysis (see Workup). Evaluation of an underlying cause must be initiated early,
frequently in the presence of concurrent treatment for acute respiratory failure. The cause of respiratory failure is often
evident after a careful history and physical examination.
Cardiogenic pulmonary edema usually develops in the context of a history of left ventricular dysfunction or valvular heart
disease. A history of previous cardiac disease, recent symptoms of chest pain, paroxysmal nocturnal dyspnea, and
orthopnea suggest cardiogenic pulmonary edema. Noncardiogenic edema (eg, acute respiratory distress syndrome [ARDS])
occurs in typical clinical contexts, such as sepsis, trauma, aspiration, pneumonia, pancreatitis, drug toxicity, and multiple
transfusions.
A study by Canet et al, examining acute respiratory failure in kidney transplant recipients, determined that 200 of 6,819
kidney transplant recipients required admission to the intensive care unit (ICU) for acute respiratory failure, which was
associated with high mortality and graft loss rates.[6] Early ICU admission and increased bacterial and Pneumocystis
prophylaxis may improve outcomes.
Physical Examination
The signs and symptoms of acute respiratory failure reflect the underlying disease process and the associated hypoxemia
or hypercapnia. Localized pulmonary findings reflecting the acute cause of hypoxemia (eg, pneumonia, pulmonary edema,
asthma, or chronic obstructive pulmonary disease [COPD]), may be readily apparent. In patients with ARDS, the
manifestations may be remote from the thorax, such as abdominal pain or long-bone fracture. Neurologic manifestations
include restlessness, anxiety, confusion, seizures, or coma.
Asterixis may be observed with severe hypercapnia. Tachycardia and a variety of arrhythmias may result from hypoxemia
and acidosis.
Cyanosis, a bluish color of skin and mucous membranes, indicates hypoxemia. Visible cyanosis typically is present when
the concentration of deoxygenated hemoglobin in the capillaries or tissues is at least 5 g/dL.
Dyspnea, an uncomfortable sensation of breathing, often accompanies respiratory failure. Excessive respiratory effort, vagal
receptors, and chemical stimuli (hypoxemia and/or hypercapnia) all may contribute to the sensation of dyspnea.
Both confusion and somnolence may occur in respiratory failure. Myoclonus and seizures may occur with severe
hypoxemia. Polycythemia is a complication of long-standing hypoxemia.
Pulmonary hypertension frequently is present in chronic respiratory failure. Alveolar hypoxemia potentiated by hypercapnia
causes pulmonary arteriolar constriction. If chronic, this is accompanied by hypertrophy and hyperplasia of the affected
smooth muscles and narrowing of the pulmonary arterial bed. The increased pulmonary vascular resistance increases
afterload of the right ventricle, which may induce right ventricular failure. This, in turn, causes enlargement of the liver and
peripheral edema. The entire sequence is known as cor pulmonale.
Criteria for the diagnosis of ARDS include the following:
Clinical presentation - Tachypnea and dyspnea; crackles upon auscultation
Clinical setting - Direct insult (aspiration) or systemic process causing lung injury (sepsis)
Radiologic appearance - 3-quadrant or 4-quadrant alveolar flooding
Lung mechanics - Diminished compliance (< 40 mL/cm water)
Gas exchange - Severe hypoxia refractory to oxygen therapy (ratio of arterial oxygen tension to fractional
concentration of oxygen in inspired gas [PaO2/FiO2] < 200)
Normal pulmonary vascular properties - Pulmonary capillary wedge pressure lower than 18 mm Hg
Complications
Complications of acute respiratory failure may be pulmonary, cardiovascular, gastrointestinal (GI), infectious, renal, or
nutritional.
Common pulmonary complications of acute respiratory failure include pulmonary embolism, barotrauma, pulmonary fibrosis,
and complications secondary to the use of mechanical devices. Patients are also prone to develop nosocomial pneumonia.
Regular assessment should be performed by periodic radiographic chest monitoring. Pulmonary fibrosis may follow acute
lung injury associated with ARDS. High oxygen concentrations and the use of large tidal volumes may worsen acute lung
injury.
Common cardiovascular complications in patients with acute respiratory failure include hypotension, reduced cardiac output,
arrhythmia, endocarditis, and acute myocardial infarction. These complications may be related to the underlying disease
process, mechanical ventilation, or the use of pulmonary artery catheters.
The major GI complications associated with acute respiratory failure are hemorrhage, gastric distention, ileus, diarrhea, and
pneumoperitoneum. Stress ulceration is common in patients with acute respiratory failure; the incidence can be reduced by
routine use of antisecretory agents or mucosal protectants.
Nosocomial infections, such as pneumonia, urinary tract infections, and catheter-related sepsis, are frequent complications
of acute respiratory failure. These usually occur with the use of mechanical devices. The incidence of nosocomial
pneumonia is high and associated with significant mortality.
Acute renal failure and abnormalities of electrolytes and acid-base homeostasis are common in critically ill patients with
respiratory failure. The development of acute renal failure in a patient with acute respiratory failure carries a poor prognosis
and high mortality. The most common mechanisms of renal failure in this setting are renal hypoperfusion and the use of
nephrotoxic drugs (including radiographic contrast material).
Nutritional complications include malnutrition and its effects on respiratory performance and complications related to
administration of enteral or parenteral nutrition. Complications associated with nasogastric tubes, such as abdominal
distention and diarrhea, also may occur. Complications of parenteral nutrition may be mechanical (resulting from catheter
insertion), infectious, or metabolic (eg, hypoglycemia, electrolyte imbalance).
DDx
Diagnostic Considerations
Respiratory failure is a common and a life-threatening condition that demands prompt diagnosis and assessment and
appropriate management.
Failure to visualize an obvious abnormality on chest radiographs in hypoxemic respiratory failure suggests the possibility of
right-to-left shunting.
The vast majority of patients in acute respiratory failure due to cardiogenic pulmonary edema respond to measures to
reduce preload and afterload. Those with acute respiratory distress syndrome (ARDS) require early elective intubation
because the duration of respiratory failure is longer.
Hypercapnic respiratory failure occurs secondary to a variety of causes, including an increased respiratory muscle load,
impaired neuromuscular function, and decreased respiratory drive caused by central nervous system (CNS) depression.
Differential Diagnoses
Acute Respiratory Distress Syndrome
Angina Pectoris
Aspiration Pneumonitis and Pneumonia
Asthma
Atelectasis
Bacterial Pneumonia
Cardiogenic Pulmonary Edema
Cardiogenic Shock
Community-Acquired Pneumonia (CAP)
Cor Pulmonale
Cyanosis
Diaphragmatic Paralysis
Dilated Cardiomyopathy
Distributive Shock
Emphysema
Hypertrophic Cardiomyopathy
Idiopathic Pulmonary Fibrosis (IPF)
Interstitial (Nonidiopathic) Pulmonary Fibrosis
Mechanical Ventilation
Myocardial Infarction
Neurogenic Pulmonary Edema
Noninvasive Ventilation
Obstructive Sleep Apnea (OSA)
Pneumothorax Imaging
Idiopathic Pulmonary Arterial Hypertension
Pulmonary Embolism (PE)
Respiratory Acidosis
Restrictive Lung Disease
Pulmonary Arterial Hypertension
Viral Pneumonia
Workup
Workup
Approach Considerations
Respiratory failure may be associated with a variety of clinical manifestations. However, these are nonspecific, and very
significant respiratory failure may be present without dramatic signs or symptoms. This emphasizes the importance of
measuring arterial blood gases in all patients who are seriously ill or in whom respiratory failure is suspected.
Chest radiography is essential. Echocardiography is not routinely done but is sometimes useful. Pulmonary functions tests
(PFTs), if feasible, may be helpful, although more useful in terms of defining recovery potential. Electrocardiography (ECG)
should be performed to evaluate the possibility of a cardiovascular cause of respiratory failure; it also may detect
dysrhythmias resulting from severe hypoxemia or acidosis. Right-sided heart catheterization is controversial.
Laboratory Studies
Once respiratory failure is suspected on clinical grounds, arterial blood gas analysis should be performed to confirm the
diagnosis and to assist in the distinction between acute and chronic forms. This helps assess the severity of respiratory
failure and helps guide management.
A complete blood cell (CBC) count may indicate anemia, which can contribute to tissue hypoxia, whereas polycythemia may
indicate chronic hypoxemic respiratory failure.
A chemistry panel may be helpful in the evaluation and management of a patient in respiratory failure. Abnormalities in renal
and hepatic function may either provide clues to the etiology of respiratory failure or alert the clinician to complications
associated with respiratory failure. Abnormalities in electrolytes such as potassium, magnesium, and phosphate may
aggravate respiratory failure and other organ function.
Measuring serum creatine kinase with fractionation and troponin I helps exclude recent myocardial infarction in a patient
with respiratory failure. An elevated creatine kinase level with a normal troponin I level may indicate myositis, which
occasionally can cause respiratory failure.
In chronic hypercapnic respiratory failure, serum levels of thyroid-stimulating hormone (TSH) should be measured to
evaluate the possibility of hypothyroidism, a potentially reversible cause of respiratory failure.
Radiography
Chest radiography is essential in the evaluation of respiratory failure because it frequently reveals the cause (see the
images below). However, distinguishing between cardiogenic and noncardiogenic pulmonary edema is often difficult.
Increased heart size, vascular redistribution, peribronchial cuffing, pleural effusions, septal lines, and perihilar bat-wing
distribution of infiltrates suggest hydrostatic edema; the lack of these findings suggests acute respiratory distress syndrome
(ARDS).
Bilateral airspace infiltrates on chest radiograph film secondary to acute respiratory distress syndrome that resulted in
respiratory failure.
Extensive left-lung pneumonia caused respiratory failure; the mechanism of hypoxia is intrapulmonary shunting.
A 44-year-old woman developed acute respiratory failure and diffuse bilateral infiltrates. She met the clinical criteria for
the diagnosis of acute respiratory distress syndrome. In this case, the likely cause was urosepsis.
This patient developed acute respiratory failure that turned out to be the initial presentation of systemic lupus
erythematosus. The lung pathology evidence of diffuse alveolar damage is the characteristic lesion of acute lupus
pneumonitis.
Echocardiography
Echocardiography need not be performed routinely in all patients with respiratory failure. However, it is a useful test when a
cardiac cause of acute respiratory failure is suspected.
The findings of left ventricular dilatation, regional or global wall motion abnormalities, or severe mitral regurgitation support
the diagnosis of cardiogenic pulmonary edema. A normal heart size and normal systolic and diastolic function in a patient
with pulmonary edema would suggest ARDS.
Echocardiography provides an estimate of right ventricular function and pulmonary artery pressure in patients with chronic
hypercapnic respiratory failure.
Pulmonary Function Tests

Patients with acute respiratory failure generally are unable to perform PFTs; however, these tests are useful in the
evaluation of chronic respiratory failure.
Normal values for forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) suggest a disturbance in
respiratory control. A decrease in the FEV1 -to-FVC ratio (FEV1/FVC) indicates airflow obstruction, whereas a reduction in
both FEV1 and FVC and maintenance of FEV1/FVC suggest restrictive lung disease.
Respiratory failure is uncommon in obstructive diseases when FEV1 is greater than 1 L and in restrictive diseases when
FVC is greater than 1 L.
See Pulmonary Function Testing for further details.
Right-Sided Heart Catheterization

Right-sided heart catheterization (also known as pulmonary artery catheterization or Swan-Ganz catheterization) remains a
controversial issue in the management of critically ill patients. Invasive monitoring probably is not routinely needed in
patients with acute hypoxemic respiratory failure, but when significant uncertainty about cardiac function, adequacy of
volume resuscitation, and systemic oxygen delivery remain, right-sided heart catheterization should be considered.
Measurement of pulmonary capillary wedge pressure may be helpful in distinguishing cardiogenic from noncardiogenic
edema. The pulmonary capillary wedge pressure should be interpreted in the context of serum oncotic pressure and cardiac
function.
Treatment
Approach Considerations
The risks of oxygen therapy are oxygen toxicity and carbon dioxide narcosis. Pulmonary oxygen toxicity rarely occurs when
a fractional concentration of oxygen in inspired gas (FiO2) lower than 0.6 is used; therefore, an attempt to lower the inspired
oxygen concentration to this level should be made in critically ill patients.
Carbon dioxide narcosis occasionally occurs when some patients with hypercapnia are given oxygen to breathe. Arterial
carbon dioxide tension (PaCO2) increases sharply and progressively with severe respiratory acidosis, somnolence, and
coma. The mechanism is primarily the reversal of pulmonary vasoconstriction and the increase in dead space ventilation.
Hypoxemia is the major immediate threat to organ function. After the patient’s hypoxemia is corrected and the ventilatory
and hemodynamic status have stabilized, every attempt should be made to identify and correct the underlying
pathophysiologic process that led to respiratory failure in the first place. The specific treatment depends on the etiology of
respiratory failure.
Patients generally are prescribed bed rest during early phases of respiratory failure management. However, ambulation as
soon as possible helps ventilate atelectatic areas of the lung.
Consultation with a pulmonary specialist and an intensivist are often required. Patients with acute respiratory failure or
exacerbations of chronic respiratory failure need to be admitted to the intensive care unit for ventilatory support.
Correction of Hypoxemia
The first objective in the management of respiratory failure is to reverse and/or prevent tissue hypoxia. Hypercapnia
unaccompanied by hypoxemia generally is well tolerated and probably is not a threat to organ function unless accompanied
by severe acidosis. Many experts believe that hypercapnia should be tolerated until the arterial blood pH falls below 7.2.
Appropriate management of the underlying disease obviously is an important component in the management of respiratory
failure.
A patient with acute respiratory failure generally should be admitted to a respiratory care unit or intensive care unit (ICU).
Most patients with chronic respiratory failure can be treated at home with oxygen supplementation and/or ventilatory assist
devices along with therapy for their underlying disease.
Extracorporeal membrane oxygenation (ECMO) may be more effective than conventional management for patients with
severe but potentially reversible respiratory failure.
Peek et al found that survival without severe disability was significantly higher in patients who were transferred to a single
specialized center for consideration of ECMO.[7] In a randomized, controlled trial in 180 patients either with a Murray lung
injury score of 3.0 or higher or with uncompensated hypercapnia and a pH lower than 7.20 despite optimal conventional
treatment, 36.7% of patients in the ECMO arm had died or were severely disabled 6 months after randomization, compared
with 52.9% of patients in the conventional treatment arm.
Although average total costs were more than twice as high for ECMO than for conventional care in this study, lifetime
quality-adjusted life-years (QALYs) gained were 10.75 for the ECMO group and 7.31 for the conventional group.[7]
Assurance of an adequate airway is vital in a patient with acute respiratory distress. The most common indication for
endotracheal intubation is respiratory failure. Endotracheal intubation serves as an interface between the patient and the
ventilator. Another indication is airway protection in patients with altered mental status.
Once the airway is secured, attention is turned toward correcting the underlying hypoxemia, the most life-threatening facet
of acute respiratory failure. The goal is to assure adequate oxygen delivery to tissues, generally achieved with an arterial
oxygen tension (PaO2) of 60 mm Hg or an arterial oxygen saturation (SaO2) greater than 90%. Supplemental oxygen is
administered via nasal prongs or face mask; however, in patients with severe hypoxemia, intubation and mechanical
ventilation are often required.
Coexistent hypercapnia and respiratory acidosis may have to be addressed. This is done by correcting the underlying cause
or providing ventilatory assistance.
While correcting for hypoxemia, the physiologic parameters have to be remembered. One of the concepts relevant to
mechanical ventilation is the so-called “driving pressure” or “transmural pressure”. For any hollow structure (be it the heart
or lung), the distending pressure is defined by the difference between the cavity pressure—in this case, the airway
pressures—and the intrathoracic pressures. The difference between these two pressures is the determinant of the driving
pressure and in the case of a stiff chest wall due to blunt trauma, burns, or increased intra-abdominal pressures, the extra-
alveolar pressures may overcome the alveolar pressures and decrease the effective distending pressures. To address this
concept, work by Talmor and others used an approach to guide the mechanical ventilation with the use of esophageal
manometry.[8] In this work, esophageal pressures were used as a surrogate for intrathoracic pressures and these numbers
were subtracted from airway pressures to define the actual driving pressures. The study was conducted in patients with
ARDS and they were able to show decreased inflammatory cytokines in the intervention group.
Principles of Mechanical Ventilation

Mechanical ventilation is used for two essential reasons: (1) to increase PaO2 and (2) to lower PaCO2. Mechanical
ventilation also rests the respiratory muscles and is an appropriate therapy for respiratory muscle fatigue.
The use of mechanical ventilation during the polio epidemics of the 1950s was the impetus that led to the development of
the discipline of critical care medicine. Before the mid-1950s, negative-pressure ventilation with the use of iron lungs was
the predominant method of ventilatory support. Currently, virtually all mechanical ventilatory support for acute respiratory
failure is provided by positive-pressure ventilation. Nevertheless, negative-pressure ventilation still is used occasionally in
patients with chronic respiratory failure.
Types of mechanical ventilation
Over the years, mechanical ventilators have evolved from simple pressure-cycled machines to sophisticated
microprocessor-controlled systems. The following is a brief overview of the basic principles of their use.
Positive-pressure versus negative-pressure ventilation
For air to enter the lungs, a pressure gradient must exist between the airway and the alveoli. This can be accomplished
either by raising pressure at the airway (positive-pressure ventilation) or by lowering pressure at the level of the alveolus
(negative-pressure ventilation).
The iron lung or tank ventilator is the most common type of negative-pressure ventilator used in the past. These ventilators
work by creating subatmospheric pressure around the chest, thereby lowering pleural and alveolar pressure and facilitating
flow of air into the patient’s lungs. These ventilators are bulky and poorly tolerated and are not suitable for use in modern
critical care units. Positive-pressure ventilation can be achieved via an endotracheal or tracheostomy tube or noninvasively
through a nasal mask or face mask.
Controlled versus patient-initiated ventilation
Ventilatory assistance can be controlled or patient-initiated. In controlled ventilation, the ventilator delivers assistance
independent of the patient’s own spontaneous inspiratory efforts. In contrast, during patient-initiated ventilation, the
ventilator delivers assistance in response to the patient’s own inspiratory efforts. The patient’s inspiratory efforts can be
sensed either by pressure or flow-triggering mechanisms.
Pressure-targeted versus volume-targeted ventilation
During positive-pressure ventilation, either pressure or volume may be set as the independent variable.
In volume-targeted (or volume preset) ventilation, tidal volume is the independent variable set by the physician or respiratory
therapist, and airway pressure is the dependent variable. In this type of ventilation, airway pressure is a function of the set
tidal volume and inspiratory flow rate, the patient’s respiratory mechanics (compliance and resistance), and the patient’s
respiratory muscle activity.
In pressure-targeted (or pressure preset) ventilation, airway pressure is the independent variable, and tidal volume is the
dependent variable. The tidal volume during pressure-targeted ventilation is a complex function of inspiratory time, the
patient’s respiratory mechanics, and the patient’s own respiratory muscle activity.
Endotracheal intubation
Mechanical ventilation requires an interface between the patient and the ventilator. In the past, this invariably occurred
through an endotracheal or tracheostomy tube, but there is a growing trend toward noninvasive ventilation, which can be
accomplished by the use of either a full face mask (covering both the nose and mouth) or a nasal mask (see Noninvasive
Ventilatory Support).[9] Care of an endotracheal tube includes correct placement of the tube, maintenance of proper cuff
pressure, and suctioning to maintain a patent airway.
After intubation, the position of the tube in the airway (rather than the esophagus) should be confirmed by auscultation of the
chest and, ideally, by a carbon dioxide detector. As a general rule, the endotracheal tube should be inserted to an average
depth of 23 cm in men and 21 cm in women (measured at the incisor). Confirming proper placement of the endotracheal
tube with a chest radiograph is recommended.
The tube should be secured to prevent accidental extubation or migration into the mainstem bronchus, and the endotracheal
tube cuff pressure should be monitored periodically. The pressure in the cuff generally should not exceed 25 mm Hg.
Endotracheal suctioning can be accomplished via either open-circuit or closed-circuit suction catheters. Routine suctioning
is not recommended, because suctioning may be associated with a variety of complications, including desaturation,
arrhythmias, bronchospasm, severe coughing, and introduction of secretions into the lower respiratory tract.
Ventilator modes
Pressure support ventilation (PSV) can be categorized as patient-initiated, pressure-targeted ventilation. With PSV,
ventilatory assistance occurs only in response to the patient’s spontaneous inspiratory efforts. With each inspiratory effort,
the ventilator raises airway pressure by a preset amount. When the inspiratory flow rate decays to a minimal level or to a
percentage of initial inspiratory flow (eg, 25% of peak flow), inspiration is terminated.
During PSV, patients are free to choose their own respiratory rate; inspiratory time, inspiratory flow rate, and tidal volume
are determined, in part, by the patient’s respiratory efforts. This mode of ventilation should not be used in patients with
unstable ventilatory drive, and care must be exercised when the patient’s respiratory mechanics are changing because of
bronchospasm, secretions, or varying levels of auto–positive end-expiratory pressure (auto-PEEP).
Intermittent mandatory ventilation (IMV) is a mode whereby mandatory breaths are delivered at a set frequency, tidal
volume, and inspiratory flow rate. However, the patient can breathe spontaneously between the machine-delivered breaths.
Most modern ventilators are capable of synchronized IMV (SIMV), whereby the ventilator attempts to deliver the mandatory
breaths in synchrony with the patient’s own inspiratory efforts. In essence, the ventilator allows the patient an opportunity to
breathe. If the patient makes an inspiratory effort during a window of time determined by the IMV rate, the ventilator delivers
a mandatory breath in response to the patient’s inspiratory effort. However, if no inspiratory effort is detected by the
ventilator, a time-triggered breath is delivered.
Compared with standard IMV, SIMV may improve patient comfort and may limit dynamic hyperinflation, which may occur
when a preset breath is delivered immediately after the patient’s spontaneous inspiratory effort (ie, before exhalation).
In assist-control ventilation, patients receive a fixed tidal volume and inspiratory flow rate with each inspiratory effort,
regardless of their respiratory rate. However, a backup rate is selected that guarantees that the patient receives a minimum
number of breaths per minute. If the patient’s respiratory rate falls below the backup rate, the ventilator delivers the number
of breaths necessary to reach that rate; such breaths are delivered independent of any inspiratory effort by the patient.
In volume-control mode, respiratory rate, tidal volume, and inspiratory flow rate (or inspiratory time) are fixed. This mode is
used most often in heavily sedated or paralyzed patients.
In pressure-control mode, as contrasted with volume-control mode, airway pressure is raised by a set amount at a fixed
number of times per minute. The physician or respiratory therapist also sets the inspiratory-to-expiratory (I:E) ratio or the
inspiratory time. This mode is used most often in heavily sedated or paralyzed patients.
Pressure-control inverse-ratio ventilation (PCIRV) is a variation of simple pressure-control ventilation. In this mode,
inspiration is set to be longer than expiration. The I:E ratio should rarely, if ever, exceed 3:1.
Triggering mechanisms
In patient-initiated (assisted) ventilation, the ventilator must sense the patient’s inspiratory effort in order to deliver
assistance. Ventilator triggering may be based on a change in either pressure or flow.
With pressure triggering, the ventilator is set to detect a certain change in pressure. The ventilator is triggered whenever
airway pressure drops by the set amount. For example, in a patient on no positive end-expiratory pressure (PEEP) with a
trigger sensitivity set at 1 cm water, a breath is triggered whenever airway pressure falls below –1 cm water. In a patient on
5 cm water PEEP with the same trigger sensitivity, a breath is triggered whenever airway pressure falls below +4 cm water.
With flow triggering, a continuous flow of gas is sent through the ventilator circuit. In some ventilators, this continuous flow
rate may be set by the physician or respiratory therapist, whereas in other ventilators, the continuous flow rate is fixed. A
flow sensitivity is selected, and the ventilator senses the patient’s inspiratory efforts by detecting a change in flow.
When the patient makes an inspiratory effort, some of the gas that was previously flowing continuously through the circuit is
diverted to the patient. The ventilator senses the decrease in flow returning through the circuit, and a breath is triggered.
One problem with flow triggering is that automatic triggering sometimes results from leaks in the ventilator circuit.
Positive end-expiratory pressure
By maintaining airway (and hence alveolar) pressure greater than zero, PEEP may recruit atelectatic alveoli and prevent
their collapse during the succeeding expiration. PEEP also shifts lung water from the alveoli into the perivascular interstitial
space and helps with recruitment of alveoli. However, it does not decrease the total amount of extravascular lung water.
In patients with disorders such as acute respiratory distress syndrome (ARDS) or acute lung injury (ALI), PEEP is applied to
recruit atelectatic alveoli, thereby improving oxygenation and allowing a reduction in FiO2 to nontoxic levels (< 0.6).
Applying PEEP of 3-5 cm water to prevent a decrease in functional residual capacity in patients with normal lungs is a
common practice.
In an ARDS Network trial, higher PEEP produced better oxygenation and lung compliance but no benefit to survival, time on
ventilator, or nonpulmonary organ dysfunction.[3] Although sufficient PEEP is essential in ventilator management of patients
with ARDS, this level varies from patient to patient. Ideal PEEP helps to achieve adequate oxygenation and decrease the
requirement for high fractions of inspiratory oxygen without causing any of the harmful effects of PEEP.
Current evidence does not support routine application of high PEEP strategy in people with ALI or ARDS; however, a study
by Briel et al found higher PEEP levels have been associated with improved survival among patients with ARDS.[10]
PEEP causes an increase in intrathoracic pressure, which may decrease venous return and cardiac output, particularly in
patients with hypovolemia.
Inspiratory flow
In volume-targeted ventilation, inspiratory flow is a variable that is set by the physician or respiratory therapist. The
inspiratory flow rate is selected on the basis of a number of factors, including the patient’s inspiratory drive and the
underlying disease.
Two flow patterns are used commonly: (1) a constant-flow (ie, square-wave) pattern (see the image below) and (2) a
decelerating-flow pattern. With a constant-flow pattern, inspiratory flow is held constant throughout the breath, whereas with
a decelerating-flow pattern, flow rises quickly to a maximal value and then decreases progressively throughout the breath.
Wave forms of a volume-targeted ventilator: Pressure, flow, and volume waveforms are shown with square-wave flow
pattern. A is baseline, B is increase in tidal volume, C is reduced lung compliance, and D is increase in flow rate. All 3
settings lead to increase in peak airway pressures. Adapted from Spearman CB et al.
In pressure-targeted ventilation, the inspiratory flow rate is a dependent variable that varies as a function of the preset
pressure and the patient’s own inspiratory effort. Because airway pressure is held constant while alveolar pressure rises
during inspiration, the pressure difference between airway and alveoli decreases, leading to a decelerating pattern of
inspiratory flow.
Ventilator-associated lung injury
Mechanical ventilation is associated with a variety of insults to the lung.
In the past, physicians focused on barotrauma, including pneumothorax, pneumomediastinum, and subcutaneous and
pulmonary interstitial emphysema. The manifestations of barotrauma probably result from excessive alveolar wall stress;
excessive airway pressure by itself does not appear to cause barotrauma. In critically ill patients, the manifestations of
barotrauma can be subtle. For example, the earliest sign of pneumothorax in supine patients may be the deep-sulcus sign
or a collection of air anteriorly along cardiophrenic angle.
It is now recognized that lung damage indistinguishable from ARDS may be caused by certain patterns of ventilatory
support. Early animal experiments showed that mechanical ventilation employing high peak airway pressures and high tidal
volume led to pulmonary edema, possibly as a result of direct parenchymal injury and altered microvascular permeability
secondary to high peak alveolar pressures. Subsequent work indicates that excessive tidal volumes resulting in alveolar
overdistention are the most important factor in ventilator-associated lung injury.
A strategy of using low tidal volumes in patients with ARDS who are on mechanical ventilation has led to a reduced
incidence of barotrauma and improved survival rates in clinical trials.
Ventilation Approaches for Specific Diseases

The mode of ventilation should be suited to the needs of the patient. After the initiation of mechanical ventilation, ventilator
settings should be adjusted on the basis of the patient’s lung mechanics, underlying disease process, gas exchange, and
response to mechanical ventilation. SIMV and assist-control ventilation are often used for the initiation of mechanical
ventilation. In patients with intact respiratory drive and mild-to-moderate respiratory failure, PSV may be a good initial
choice.
The lowest FiO2 that produces an SaO2 greater than 90% and a PaO2 greater than 60 mm Hg generally is recommended.
The prolonged use of an FiO2 lower than 0.6 is unlikely to cause pulmonary oxygen toxicity.
Acute respiratory distress syndrome
In ARDS, the primary objective of mechanical ventilation is to accomplish adequate gas exchange while avoiding excessive
inspired oxygen concentrations and alveolar overdistention.
The traditional ventilatory strategy of delivering high tidal volumes leads to high end-inspiratory alveolar pressures (ie,
plateau pressure). Many investigators now believe that repeated cycles of opening and collapsing of inflamed and
atelectatic alveoli are detrimental to the lung. Failure to maintain a certain minimum alveolar volume may further accentuate
the lung damage. Furthermore, transalveolar pressure (reflected by plateau pressure) exceeding 25-30 cm water is
considered to be an important risk factor for stretch injury to the lungs.
Patients with ARDS should be targeted to receive a tidal volume of 6 mL/kg. It is important to remember that the set tidal
volume should be based on ideal rather than actual body weight. If the plateau pressure remains excessive (>30 cm water),
further reductions in tidal volume may be necessary.
ARDSNet, a prospective randomized clinical trial, demonstrated a striking reduction in hospital mortality in ARDS patients
who were ventilated with 6 mL/kg predicted body weight rather than with 12 mL/kg.[3] Patients who received the lower tidal
volume strategy also had more ventilator-free and organ failure-free days. This strategy may lead to respiratory acidosis,
which requires either high respiratory rates and or sodium bicarbonate infusion.
Application of PEEP sufficient to raise the tidal volume above the lower inflection point (Pflex) on the pressure-volume curve
may minimize alveolar wall stress and improve oxygenation. A pressure-volume curve can be constructed for an individual
patient by measuring plateau pressures at different lung volumes (see the image below). Pflex is the point where the slope
of the curve changes, indicating that the lung is operating at the most compliant part of the curve.
Pressure-volume curve of a patient with acute respiratory distress syndrome (ARDS) on mechanical ventilation can be
constructed. The lower and the upper ends of the curve are flat, and the central portion is straight (where the lungs are
most compliant). For optimal mechanical ventilation, patients with ARDS should be kept between the inflection and the
deflection point.
A lung-protective strategy in which the PaCO2 is allowed to rise (permissive hypercapnia) may reduce barotrauma and
enhance survival.
In some patients with ARDS, the prone position may lead to significant improvements in oxygenation; whether this
translates to improved outcome is unknown.
Lower end-inspiratory (plateau) airway pressures, lower tidal volumes (VT), and higher positive end-expiratory pressures
(PEEPs) can decrease mortality in ARDS; however, the contributions of these individual components is not clear. Work by
Amato et al attempted to dissect these relations.[11] The group studied the dynamic compliance (Cdyn) in relation to VT,
and their results suggest that in this dynamic relationship, the driving pressure (ΔP=VT/Cdyn) has a better predictive value
than PEEP or VT for survival from ARDS.
Obstructive airway diseases
In patients with chronic obstructive pulmonary disease (COPD) or asthma, initiation of mechanical ventilation may worsen
dynamic hyperinflation (auto-PEEP or intrinsic PEEP [PEEPi]). The dangers of auto-PEEP include reduction in cardiac
output and hypotension (because of decreased venous return), as well as barotrauma.
The goals of mechanical ventilation in obstructive airway diseases are to unload the respiratory muscles, achieve adequate
oxygenation, and minimize the development of dynamic hyperinflation and its associated adverse consequences.
After the initiation of mechanical ventilation, patients with status asthmaticus frequently develop severe dynamic
hyperinflation, which is often associated with adverse hemodynamic effects. The development of dynamic hyperinflation can
be minimized by delivering the lowest possible minute ventilation in the least possible time. Therefore, the initial ventilatory
strategy should involve the delivery of relatively low tidal volumes (eg, 6 mL/kg) and lower respiratory rates (eg, 8-12
breaths/min) with a high inspiratory flow rate.
In the absence of hypoxia, hypercapnia generally is well tolerated in most patients. Even marked levels of hypercapnia are
preferable to attempts to normalize the carbon dioxide tension (PCO2), which could lead to dangerous levels of
hyperinflation.
Patients often require large amounts of sedation and, occasionally, paralysis until the bronchoconstriction and airway
inflammation have improved.
If a decision is made to measure trapped-gas volume (ie, end-inspiratory volume [VEI]), as recommended by some
investigators, an attempt should be made to keep it below 20 mL/kg. Routine measurement of VEI is not recommended,
because measurement of plateau pressure and auto-PEEP provide similar information and are much easier to perform.
Patients with COPD have expiratory flow limitation and are prone to the development of dynamic hyperinflation. Here again,
the goal of mechanical ventilation is to unload the respiratory muscles while minimizing the degree of hyperinflation. The use
of extrinsic PEEP may be considered in spontaneously breathing patients in order to reduce the work of breathing and to
facilitate triggering of the ventilator. Care must be exercised to avoid causing further hyperinflation, and the set level of
PEEP should always be less than the level of auto-PEEP.
Patient-ventilator synchrony
During mechanical ventilation, many patients sometimes experience asynchrony between their own spontaneous respiratory
efforts and the pattern of ventilation imposed by the ventilator. This can occur with both controlled and patient-initiated
modes of ventilation.
To achieve synchrony, the ventilator not only must sense and respond quickly to the onset of the patient’s inspiratory efforts
but also must terminate the inspiratory phase when the patient’s “respiratory clock” switches to expiration. Asynchronous
interactions (“fighting the ventilator”) may occur when ventilator breaths and patient efforts are out of phase. This may lead
to excessive work of breathing, increased respiratory muscle oxygen consumption, and decreased patient comfort.
There are several ways of minimizing patient-ventilator asynchrony. Modern ventilators are equipped with significantly better
valve characteristics than older-generation ventilators had. In addition, flow triggering (with a continuous flow rate) appears
to be more sensitive and more responsive to patient’s spontaneous inspiratory efforts.
Patient-ventilator asynchrony often occurs in the presence of auto-PEEP. Auto-PEEP creates an inspiratory threshold load
and thereby decreases the effective trigger sensitivity. This may be partially offset by the application of external PEEP.
Sometimes, additional sedation may be necessary to achieve adequate patient-ventilator synchrony.
Noninvasive Ventilatory Support

Ventilatory support via a nasal or full-face mask rather than via an endotracheal tube (see the images below) is increasingly
being employed for patients with acute or chronic respiratory failure. Noninvasive ventilation should be considered in
patients with mild-to-moderate acute respiratory failure. The patient should have an intact airway, airway-protective reflexes,
and be alert enough to follow commands.
Headgear and full face mask commonly are used as the interface for noninvasive ventilatory support.
Noninvasive ventilation with bilevel positive airway pressure for acute respiratory failure secondary to exacerbation of
chronic obstructive pulmonary disease.
In clinical trials, noninvasive positive-pressure ventilation (NPPV) has proven beneficial in acute exacerbations of COPD and
asthma, decompensated congestive heart failure (CHF) with mild-to-moderate pulmonary edema, and pulmonary edema
from hypervolemia. Reports conflict regarding its efficacy in acute hypoxemia due to other causes (eg, pneumonia). A
variety of methods and systems are available for delivering noninvasive ventilatory support.
The benefits of NPPV depend on the underlying cause of respiratory failure. In acute exacerbations of obstructive lung
disease, NPPV decreases PaCO2 by unloading the respiratory muscles and supplementing alveolar ventilation. The results
of several clinical trials support the use of NPPV in this setting.
In a large randomized trial comparing NPPV with a standard ICU approach, the use of NPPV was shown to reduce
complications, duration of ICU stay, and mortality.[12] In patients in whom NPPV failed, mortality rates were similar to the
intubated group (25% vs 30%).
In the largest prospective randomized study comparing NPPV with standard treatment in patients with COPD exacerbation,
Plant et al found that treatment failed in significantly more patients in the control group (27% vs 15%) and that in-hospital
mortality rates were significantly reduced by NPPV (20% to 10%). NPPV was administered on the ward; the nurses were
trained for 8 hours in the preceding 3 months.[13]
In addition, 3 Italian cohort studies with historical or matched control groups have suggested that long-term outcome of
patients treated with NPPV is better than that of patients treated with medical therapy and/or endotracheal intubation.[14,
15, 16]
In acute hypoxemic respiratory failure, NPPV also helps maintain an adequate PaO2 until the patient improves. In
cardiogenic pulmonary edema, NPPV improves oxygenation, reduces work of breathing, and may increase cardiac output.
When applied continuously to patients with chronic ventilatory failure, NPPV provides sufficient oxygenation or carbon
dioxide elimination to sustain life by reversing or preventing atelectasis or resting the respiratory muscles.
Patients with obesity-hypoventilation syndrome benefit from NPPV as a consequence of reversal of the alveolar
hypoventilation and upper-airway obstruction.
Most studies have used NPPV as an intermittent rather than continuous mode of support. Most trials have used inspiratory
pressures of 12-20 cm water and expiratory pressures of 0-6 cm water and have excluded patients with hemodynamic
instability, uncontrolled arrhythmia, or a high risk of aspiration.
Weaning From Ventilator

Weaning or liberation from mechanical ventilation is initiated when the underlying process that necessitated ventilatory
support has improved. In some patients, such as those recovering from uncomplicated major surgery or a toxic ingestion,
withdrawal of ventilator support may be done without weaning. In patients who required more prolonged respiratory therapy,
the process of liberating the patient from ventilatory support may take much longer.
A patient who has stable underlying respiratory status, adequate oxygenation (eg, PaO2/FiO2 >200 on PEEP < 10 cm
water), intact respiratory drive, and stable cardiovascular status should be considered for discontinuance of mechanical
ventilation.
Many criteria have been used to predict success in weaning, including a minute ventilation of less than 10 L/min, maximal
inspiratory pressure more than –25 cm water, vital capacity more than 10 mL/kg, absence of dyspnea, absence of
paradoxical respiratory muscle activity, and agitation or tachycardia during the weaning trial. However, the rapid-shallow
breathing index—that is, the patient’s tidal volume (in liters) divided by the respiratory rate (in breaths/min) during a period of
spontaneous breathing—may be a better predictor of successful extubation.
In one study, a daily trial of spontaneous breathing in patients with a rapid-shallow breathing index of less than 105 resulted
in a shorter duration of mechanical ventilation. A spontaneous breathing trial of only 30 minutes appears adequate to
identify patients in whom successful extubation is likely.
In patients who are not yet ready to be liberated from the ventilator, one should focus on the cause of ventilator dependency,
such as excessive secretions, inadequate respiratory drive, impaired cardiac function, and ventilatory muscle weakness,
rather than the type of ventilator or the mode of assistance.
The weaning protocol could be designed with assist-control ventilation, with gradually increasing time spent in trials of
spontaneous breathing or by gradually reducing the level of PSV. SIMV appears to result in less rapid weaning than PSV or
trials of spontaneous breathing. Patient-ventilator desynchrony is an important component in a carefully designed weaning
protocol. Attention must be directed toward patient comfort, avoidance of fatigue, adequate nutrition, and prevention and
treatment of medical complications during the weaning period.
Peak inspiratory and plateau pressures should be assessed frequently. Attempts should be made to limit the plateau
pressure to less than 25 cm water. Expiratory volume is checked initially and periodically (continuously if ventilator-capable)
to assure that the set tidal volume is delivered. In patients with severe airflow obstruction, auto-PEEP (PEEPi) should be
monitored on a regular basis.
Long-Term Monitoring
A patient with respiratory failure requires repeated assessments, which may range from bedside observations to the use of
invasive monitoring. These patients should be admitted to a facility where close observation can be provided. Most patients
who require mechanical ventilation are critically ill; therefore, constant monitoring in a critical care setting is a must.
Cardiac monitoring, blood pressure, pulse oximetry, SaO2, and capnometry are recommended. An arterial blood gas
determination should be obtained 15-20 minutes after the institution of mechanical ventilation. The pulse oximetry readings
direct efforts to reduce FiO2 to a value less than 0.6, and the PaCO2 guides adjustments of minute ventilation.
Guidelines
Guidelines Summary
Summary of guidelines on acute respiratory failure (ARF) by the European Respiratory
Society/American Thoracic Society
Bilevel noninvasive mechanical ventilation (NIV) may be considered in chronic obstructive pulmonary disease (COPD)
patients with an acute exacerbation in the following three clinical settings[17] :
To prevent acute respiratory acidosis (ie, when the arterial carbon dioxide tension [PaCO 2] is normal or elevated but
pH is normal)
To prevent endotracheal intubation and invasive mechanical ventilation in patients with mild-to-moderate acidosis
and respiratory distress, with the aim of preventing deterioration to a point when invasive ventilation would be
considered
As an alternative to invasive ventilation in patients with severe acidosis and more severe respiratory distress
Bilevel NIV also may be used as the only method for providing ventilatory support in patients who are not candidates for or
decline invasive mechanical ventilation.[17]
Bilevel NIV is recommended as follows[17] :
Patients with ARF leading to acute or acute-on-chronic respiratory acidosis (pH ≤7.35) due to COPD exacerbation
Patients considered to require endotracheal intubation and mechanical ventilation, unless the patient is immediately
deteriorating
Either bilevel NIV or continuous positive airway pressure (CPAP) is recommended for patients with ARF due to cardiogenic
pulmonary edema.[17]
CPAP or bilevel NIV is suggested for patients with ARF due to cardiogenic pulmonary edema in the prehospital setting.[17]
Early NIV is suggested for immunocompromised patients with ARF.[17]
NIV use is suggested as follows[17] :
For patients with postoperative ARF

Can be offered to dyspneic patients for palliation in the setting of terminal cancer or other terminal conditions
For the prevention of postextubation respiratory failure in high-risk patients; not suggested to prevent postextubation
respiratory failure in non–high-risk patients
To facilitate weaning from mechanical ventilation in patients with hypercapnic respiratory failure
Medication
Medication Summary
Pharmacotherapy for cardiogenic pulmonary edema and acute exacerbations of chronic obstructive pulmonary disease
(COPD) is discussed here. The goals of therapy in cardiogenic pulmonary edema are to achieve a pulmonary capillary
wedge pressure of 15-18 mm Hg and a cardiac index greater than 2.2 L/min/m2 while maintaining adequate blood pressure
and organ perfusion. These goals may have to be modified for some patients. Diuretics, nitrates, analgesics, and inotropes
are used in the treatment of acute pulmonary edema.
Diuretics, Other
Class Summary
First-line therapy generally includes a loop diuretic such as furosemide, which inhibits sodium chloride reabsorption in the
ascending loop of Henle.
Furosemide (Lasix)
Administer loop diuretics such as furosemide intravenously (IV) because this allows both superior potency and a higher
peak concentration despite an increased incidence of adverse effects, particularly ototoxicity.
Metolazone (Zaroxolyn)
Metolazone has been used as adjunctive therapy in patients initially refractory to furosemide. It has been demonstrated to
be synergistic with loop diuretics in treating refractory patients and causes a greater loss of potassium. Metolazone is a
potent thiazide-related diuretic that sometimes is used in combination with furosemide for more aggressive diuresis. It is
also used for initiating diuresis in patients with a degree of renal dysfunction.
Nitrates
Class Summary
Nitrates reduce myocardial oxygen demand by lowering preload and afterload. In severely hypertensive patients,
nitroprusside causes more arterial dilatation than nitroglycerin. Nevertheless, in view of the possibility of thiocyanate toxicity
and the coronary steal phenomenon associated with nitroprusside, IV nitroglycerin may be the initial therapy of choice for
afterload reduction.
Nitroglycerin sublingual (Nitro-Bid, NitroMist, Nitrostat, Nitrolingual)

Sublingual nitroglycerin tablets and spray are particularly useful in the patient who presents with acute pulmonary edema
with a systolic blood pressure of at least 100 mm Hg. As with sublingual nitroglycerin tablets, the onset of action of
nitroglycerin spray is 1-3 minutes, with a half-life of 5 minutes. Administration of the spray may be easier, and it can be
stored for as long as 4 years.
Topical nitrate therapy is reasonable in a patient presenting with class I-II congestive heart failure (CHF). However, in
patients with more severe signs of heart failure or pulmonary edema, IV nitroglycerin is preferred because it is easier to
monitor hemodynamics and absorption, particularly in patients with diaphoresis. Oral nitrates, because of their delayed
absorption, play little role in the management of acute pulmonary edema.
Nitroprusside sodium (Nitropress)

Nitroprusside produces vasodilation of venous and arterial circulation. At higher dosages, it may exacerbate myocardial
ischemia by increasing heart rate. It is easily titratable.
Opioid Analgesics
Class Summary
Morphine IV is an excellent adjunct in the management of acute pulmonary edema. In addition to anxiolysis and analgesia,
its most important effect is venodilation, which reduces preload. It also causes arterial dilatation, which reduces systemic
vascular resistance and may increase cardiac output.
Morphine sulfate (Duramorph, Astramorph)

Morphine sulfate is the drug of choice for narcotic analgesia because of its reliable and predictable effects, safety profile,
and ease of reversibility with naloxone. Morphine sulfate administered IV may be dosed in a number of ways and commonly
is titrated until the desired effect is obtained.
Inotropic Agents
Class Summary
The principal inotropic agents are dopamine, dobutamine, inamrinone (formerly amrinone), milrinone, dopexamine, and
digoxin. In patients with hypotension who present with CHF, dopamine and dobutamine usually are employed. Inamrinone
and milrinone inhibit phosphodiesterase, resulting in increased intracellular cyclic adenosine monophosphate (cAMP) and
altered calcium transport. As a result, they increase cardiac contractility and reduce vascular tone by vasodilatation.
Dopamine
Dopamine is a positive inotropic agent that stimulates both adrenergic and dopaminergic receptors. Its hemodynamic effects
depend on the dose. Lower doses stimulate mainly dopaminergic receptors that produce renal and mesenteric vasodilation;
higher doses produce cardiac stimulation and renal vasodilation. Doses of 2-10 µg/kg/min can lead to tachycardia, ischemia,
and dysrhythmias. Doses higher than 10 µg/kg/min cause vasoconstriction, which increases afterload.
Norepinephrine (Levophed)
Norepinephrine is used in protracted hypotension after adequate fluid replacement. It stimulates beta1- and alpha-
adrenergic receptors, which leads to increased cardiac muscle contractility and heart rate, as well as vasoconstriction. As a
result, norepinephrine increases systemic blood pressure and cardiac output. Adjust and maintain infusion to stabilize blood
pressure (eg, 80-100 mm Hg systolic) sufficiently to perfuse vital organs.
Dobutamine
Dobutamine produces vasodilation and increases the inotropic state. At higher dosages, it may cause increased heart rates,
thus exacerbating myocardial ischemia. It is a strong inotropic agent with minimal chronotropic effect and no
vasoconstriction.
Beta2 Agonists
Class Summary
Bronchodilators are an important component of treatment in respiratory failure caused by obstructive lung disease. These
agents act to decrease muscle tone in both small and large airways in the lungs. This category includes beta-adrenergics,
methylxanthines, and anticholinergics.
Terbutaline (Brethaire, Bricanyl)

Terbutaline acts directly on beta2 receptors to relax bronchial smooth muscle, relieving bronchospasm and reducing airway
resistance.
Albuterol (Proventil)
Albuterol is a beta-agonist useful in the treatment of bronchospasm. It selectively stimulates beta2-adrenergic receptors of
the lungs. Bronchodilation results from relaxation of bronchial smooth muscle, which relieves bronchospasm and reduces
airway resistance.
Xanthine Derivatives
Class Summary
Xanthine derivatives may relax smooth muscle of the bronchi.
Theophylline (Elixophyllin Elixir, Theo-24)

Theophylline has a number of physiologic effects, including increases in collateral ventilation, respiratory muscle function,
mucociliary clearance, and central respiratory drive. It partially acts by inhibiting phosphodiesterase, elevating cellular cAMP
levels, or antagonizing adenosine receptors in the bronchi, resulting in relaxation of smooth muscle. However, its clinical
efficacy is controversial, especially in the acute setting.
Anticholinergics, Respiratory
Class Summary
Anticholinergics antagonize the action of acetylcholine with muscarinic receptor on bronchial smooth muscle.
Ipratropium bromide (Atrovent HFA)

Ipratropium bromide is an anticholinergic medication that appears to inhibit vagally mediated reflexes by antagonizing the
action of acetylcholine, specifically with the muscarinic receptor on bronchial smooth muscle. Vagal tone can be significantly
increased in COPD; therefore, this can have a profound effect. Ipratropium can be combined with a beta-agonist because it
may require 20 minutes to begin having an effect.
Corticosteroids
Class Summary
Corticosteroids have been shown to be effective in accelerating recovery from acute COPD exacerbations and are an
important anti-inflammatory therapy in asthma. Although they may not make a clinical difference in the emergency
department (ED), they have some effect 6-8 hours into therapy; therefore, early dosing is critical.
Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol)

Methylprednisolone is usually given IV in the ED for initiation of corticosteroid therapy, although in theory, oral administration
should be equally efficacious.
Questions & Answers

Overview
What is respiratory failure?
How is hypoxemic respiratory failure (type I) characterized?
How is hypercapnic respiratory failure (type II) characterized?

What are the differences between acute and chronic respiratory failure?
What is included in the workup of suspected respiratory failure?
What is the danger of hypoxemia in respiratory failure?
In which component of the respiratory system does respiratory failure originate?
What is the role of ventilatory capacity in the pathogenesis of respiratory failure?
Which processes for respiration are engaged in the pathogenesis of respiratory failure?
What is the role of gas exchange in the pathophysiology of respiratory failure?
What is the oxygen hemoglobin dissociation curve?
In which forms is carbon dioxide transported in the pathophysiology of respiratory failure?
What is the role of blood flow and ventilation in the pathophysiology of respiratory failure?
Which equation represents the relationship between the rate of carbon dioxide production by the tissues and the rate of
carbon dioxide elimination by the lung in the pathophysiology of respiratory failure?
How is the alveolar-arterial PO2 gradient measured in the pathophysiology of respiratory failure?
What are the pathophysiologic mechanisms for hypoxemic respiratory failure?
What is the role of the ventilation-to-perfusion ratio (V/Q) in the pathophysiology of respiratory failure?
What causes a low ventilation-to-perfusion ratio (V/Q) in the pathophysiology of respiratory failure?
What is the benefit of 100% oxygen for patients experiencing respiratory failure?
What is the role of shunt in the pathophysiology of respiratory failure?
What is an anatomic shunt in the pathophysiology of respiratory failure?
When is a shunt a cause of hypoxemia in respiratory failure?
How is arterial carbon dioxide tension (PaCO2) measured in the pathogenesis of respiratory failure?
What is the role of hypoventilation in the pathophysiology of respiratory failure?
How are the etiologies of respiratory failure categorized?
Which metabolic disorders of the central nervous system (CNS) lead to respiratory failure?
Which disorders of the peripheral nervous system (PNS), respiratory muscles, and chest wall lead to respiratory failure?
Which severe-upper airway disorders cause respiratory failure?
Which diseases of the alveoli can result in respiratory failure?
What are common causes of type I (hypoxemic) respiratory failure?
What are common causes of type II (hypercapnic) respiratory failure?
What is the overall prevalence of respiratory failure?
What are the racial predilections in incidence of respiratory failure?
What is the mortality rate for respiratory failure?
Presentation
How is respiratory failure diagnosed?
Which history findings suggest cardiogenic pulmonary edema resulting in respiratory failure?
What are the risk factors for respiratory failure following kidney transplantation?
What are the signs and symptoms of acute respiratory failure?
Which physical findings are characteristic of type I and type II respiratory failure?
What is the significance of a finding of cyanosis in suspected type I respiratory failure?
What may contribute to dyspnea in respiratory failure?
Which nervous system findings suggest respiratory failure?
What causes cor pulmonale occur in respiratory failure?
What are the diagnostic criteria for acute respiratory distress syndrome (ARDS)?
What are the categories of complications of acute respiratory failure (ARF)?
What are the pulmonary complications of acute respiratory failure (ARF)?
What are the cardiovascular complications of acute respiratory failure (ARF)?
What are the GI complications of acute respiratory failure (ARF)?
Which nosocomial infections are complications of respiratory failure?
Which complications are common in critically ill patients with respiratory failure?
What are the nutritional complications of acute respiratory failure (ARF)?
DDX
What is respiratory failure?
What radiographic finding suggests right-to-left shunting in respiratory failure?
When is early intubation indicated for respiratory failure?
What causes of hypercapnic respiratory failure (type II)?
What are the differential diagnoses for Respiratory Failure?
Workup
What is the role of arterial blood gas measurement in the diagnosis of respiratory failure?
What is the role of imaging in the diagnosis of respiratory failure?
How is the clinical diagnosis of respiratory failure confirmed?
What is the role of a CBC count in the diagnosis of respiratory failure?
What is the role of a chemistry panel in the evaluation of respiratory failure?
How is myocardial infarction excluded in the evaluation of respiratory failure?
What is the role of thyroid-stimulating hormone (TSH) testing in the diagnosis of respiratory failure?
What is the role of chest radiography in the diagnosis of respiratory failure?
What is the role of echocardiography in the diagnosis of respiratory failure?
What is the role of pulmonary function tests (PFTs) in the diagnosis of respiratory failure?
What is the role of right-sided heart catheterization in the diagnosis and management respiratory failure?
What is the role of the pulmonary capillary wedge pressure in the diagnosis of respiratory failure?
Treatment
What are the risks of oxygen therapy for respiratory failure?
What should be done once hypoxemia is corrected in patients with respiratory failure?
When is bed rest indicated in the treatment of respiratory failure?
Which specialist consultations are required for treatment of respiratory failure?
What is the first objective for treatment of respiratory failure?
When is inpatient care indicated for respiratory failure?

What is the role of extracorporeal membrane oxygenation (ECMO) in the treatment of respiratory failure?
What is the role of endotracheal intubation in the treatment of respiratory failure?
How is coexistent hypercapnic respiratory failure and respiratory acidosis managed?
What are the benefits of mechanical ventilation in the treatment of respiratory failure?
What is the role of negative pressure ventilation in the treatment of respiratory failure?
What is the evolution of mechanical ventilators used for the treatment of respiratory failure?
What are the differences between positive-pressure and negative-pressure ventilators for the treatment of respiratory
failure?
What are the differences between controlled and patient-initiated ventilators for the treatment of respiratory failure?
Which variables are set for positive-pressure ventilation in respiratory failure?
What is volume-targeted (or volume preset) ventilation for respiratory failure?
What is pressure-targeted (or pressure preset) ventilation for respiratory failure?
How does endotracheal intubation mechanically ventilate patients with respiratory failure?
What is pressure support ventilation (PSV) for respiratory failure?
What is intermittent mandatory ventilation (IMV) for respiratory failure?
What are the benefits of synchronized intermittent mandatory ventilation (SIMV) for respiratory failure?
What is assist-control ventilation for respiratory failure?
What is volume-control ventilation for respiratory failure?
When is pressure-control ventilation indicated for respiratory failure?
What is pressure-control inverse-ratio ventilation (PCIRV) for respiratory failure?
What is patient-initiated (assisted) ventilation for respiratory failure?
How is a pressure triggering ventilator used to treat respiratory failure?
How is a flow triggering ventilator used to treat respiratory failure?
What is positive end-expiratory pressure (PEEP) ventilation for respiratory failure?
How is positive end-expiratory pressure (PEEP) used for treatment of respiratory failure?
What is the role of positive end-expiratory pressure (PEEP) in the treatment of respiratory failure?
How does positive end-expiratory pressure (PEEP) affect intrathoracic pressure in patients with respiratory failure?
What is the role of inspiratory flow in volume-targeted ventilation for respiratory failure?
Which flow patterns are commonly used in mechanical ventilation for respiratory failure?
What is the role of inspiratory flow in pressure-targeted ventilation for respiratory failure?
What are the manifestations of barotrauma caused by mechanical ventilation for the treatment of respiratory failure?
Which factors increase the risk of lung damage from mechanical ventilation for respiratory failure?
What is the benefit of low tidal volumes in the mechanical ventilation for respiratory failure?
How is the mode of ventilation selected for the treatment of respiratory failure?
What is the recommended ventilation regimen for patients with respiratory failure?
What is the primary objective of mechanical ventilation in patients with acute respiratory distress syndrome (ARDS)?
What is the traditional ventilation strategy for acute respiratory distress syndrome (ARDS)?
How is the target tidal volume determined for patients with acute respiratory distress syndrome (ARDS)?
What can minimize alveolar wall stress and improve oxygenation in patients with acute respiratory distress syndrome
(ARDS)?
What are the benefits of a lung-protective strategy in the treatment of acute respiratory distress syndrome (ARDS)?
Why is the prone position beneficial in the treatment of acute respiratory distress syndrome (ARDS)?
What are the risks of mechanical ventilation in patients with obstructive airway disease-related respiratory failure?
What are the goals of mechanical ventilation in obstructive airway disease-related respiratory failure?
How is severe dynamic hyperinflation treated in patients with respiratory failure?
When is hypercapnia tolerated in patients with obstructive airway disease-related respiratory failure?
What is the role of sedation in the treatment of obstructive airway disease-related respiratory failure?
When is measurement of end-inspiratory volume indicated in the treatment of respiratory failure?
What is the role of positive end-expiratory pressure (PEEP) in the treatment of COPD-related respiratory failure?
When does asynchrony in the mechanical ventilation occur in the treatment of respiratory failure?
How is synchrony achieved during mechanical ventilation for respiratory failure?
How is patient-ventilator asynchrony minimized in the treatment of respiratory failure?
Why does patient-ventilator asynchrony often occur in auto-positive end-expiratory pressure (PEEP) for respiratory failure?
When is noninvasive ventilation (NIV) considered for the treatment of respiratory failure (ARF)?
What are the benefits of noninvasive positive-pressure ventilation (NPPV) in the treatment of respiratory failure?
What are the benefits of noninvasive positive-pressure ventilation (NPPV) in the treatment of acute hypoxemic respiratory
failure?
What are the benefits of noninvasive positive-pressure ventilation (NPPV) in patients with chronic respiratory failure?
What are the benefits of noninvasive positive-pressure ventilation (NPPV) the treatment of obesity-hypoventilation
syndrome-related respiratory failure?
Which mode of noninvasive positive-pressure ventilation (NPPV) is preferred for the treatment of respiratory failure?
How is weaning from mechanical ventilation initiated in patients with respiratory failure?
When should patients with respiratory failure be considered for discontinuance of mechanical ventilation?
Which criteria are used to predict success in weaning from mechanical ventilation for respiratory failure?
What should be the focus of treatment for respiratory failure in those unable to wean from mechanical ventilation?
How might a weaning protocol be designed for patients with respiratory failure?
What is the role of peak inspiratory and plateau pressure assessment in patients with respiratory failure?
What is included in the long-term monitoring of respiratory failure?
Guidelines
What are the ERS/ATS guidelines for use of bilevel noninvasive mechanical ventilation (NIV) in the treatment of COPD-
related acute respiratory failure (ARF)?
According to ERS/ATS guidelines when is bilevel noninvasive mechanical ventilation (NIV) an alternative treatment for acute
respiratory failure?
What are the ERS/ATS guidelines indications for bilevel noninvasive mechanical ventilation (NIV) in the treatment of acute
respiratory failure (ARF)?
What are the ERS/ATS recommendations for ventilation in patients with acute respiratory failure (ARF) due to cardiogenic
pulmonary edema?
What are the ERS/ATS guidelines for noninvasive mechanical ventilation (NIV) in immunocompromised patients with acute
respiratory failure?
Medications
Which medications are used in the treatment of respiratory failure?
Which medications in the drug class Corticosteroids are used in the treatment of Respiratory Failure?
Which medications in the drug class Anticholinergics, Respiratory are used in the treatment of Respiratory Failure?
Which medications in the drug class Xanthine Derivatives are used in the treatment of Respiratory Failure?
Which medications in the drug class Beta2 Agonists are used in the treatment of Respiratory Failure?
Which medications in the drug class Inotropic Agents are used in the treatment of Respiratory Failure?
Which medications in the drug class Opioid Analgesics are used in the treatment of Respiratory Failure?
Which medications in the drug class Nitrates are used in the treatment of Respiratory Failure?
Which medications in the drug class Diuretics, Other are used in the treatment of Respiratory Failure?
Contributor Information and Disclosures
Author
Ata Murat Kaynar, MD Associate Professor, Departments of Critical Care Medicine and Anesthesiology, University of
Pittsburgh School of Medicine
Ata Murat Kaynar, MD is a member of the following medical societies: American Association for the Advancement of
Science, American College of Chest Physicians, American Society of Anesthesiologists, Society of Critical Care Medicine,
Society of Critical Care Anesthesiologists
Disclosure: Nothing to disclose.
Coauthor(s)
Sat Sharma, MD, FRCPC Professor and Head, Division of Pulmonary Medicine, Department of Internal Medicine,
University of Manitoba Faculty of Medicine; Site Director, Respiratory Medicine, St Boniface General Hospital, Canada
Sat Sharma, MD, FRCPC is a member of the following medical societies: American Academy of Sleep Medicine, American
College of Chest Physicians, American College of Physicians-American Society of Internal Medicine, American Thoracic
Society, Canadian Medical Association, Royal College of Physicians and Surgeons of Canada, Royal Society of Medicine,
Society of Critical Care Medicine, World Medical Association
Chief Editor
Michael R Pinsky, MD, CM, Dr(HC), FCCP, FAPS, MCCM Professor of Critical Care Medicine, Bioengineering,
Cardiovascular Disease, Clinical and Translational Science and Anesthesiology, Vice-Chair of Academic Affairs, Department
of Critical Care Medicine, University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine
Michael R Pinsky, MD, CM, Dr(HC), FCCP, FAPS, MCCM is a member of the following medical societies: American College
of Chest Physicians, American College of Critical Care Medicine, American Thoracic Society, European Society of Intensive
Care Medicine, Society of Critical Care Medicine
Disclosure: Received income in an amount equal to or greater than $250 from: Masimo, Edwards Lifesciences, Cheetah
Medical<br/>Received honoraria from LiDCO Ltd for consulting; Received intellectual property rights from iNTELOMED for
board membership; Received honoraria from Edwards Lifesciences for consulting; Received honoraria from Masimo, Inc for
board membership. for: Received consulting fees, ExoStat .
Acknowledgements
Cory Franklin, MD Professor, Department of Medicine, Rosalind Franklin University of Medicine and Science; Director,
Division of Critical Care Medicine, Cook County Hospital
Cory Franklin, MD is a member of the following medical societies: New York Academy of Sciences and Society of Critical
Care Medicine
Harold L Manning, MD Professor, Departments of Medicine, Anesthesiology and Physiology, Section of Pulmonary and
Critical Care Medicine, Dartmouth Medical School
Harold L Manning, MD is a member of the following medical societies: American College of Chest Physicians, American
College of Physicians, and American Thoracic Society
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of
Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Medscape Salary Employment
References
1. Khan NA, Palepu A, Norena M, et al. Differences in hospital mortality among critically ill patients of Asian, Native Indian, and
European descent. Chest. 2008 Dec. 134(6):1217-22. [Medline].
2. Moss M, Mannino DM. Race and gender differences in acute respiratory distress syndrome deaths in the United States: an
analysis of multiple-cause mortality data (1979- 1996). Crit Care Med. 2002 Aug. 30(8):1679-85. [Medline].
3. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes
for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J
Med. 2000 May 4. 342(18):1301-8. [Medline].
4. Phua J, Badia JR, Adhikari NK, et al. Has mortality from acute respiratory distress syndrome decreased over time?: A
systematic review. Am J Respir Crit Care Med. 2009 Feb 1. 179(3):220-7. [Medline].
5. Noveanu M, Breidthardt T, Reichlin T, Gayat E, Potocki M, Pargger H, et al. Effect of oral beta-blocker on short and long-term
mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study. Crit Care. 2010 Nov 3. 14(6):R198.
[Medline]. [Full Text].
6. Canet E, Osman D, Lambert J, et al. Acute respiratory failure in kidney transplant recipients: a multicenter study. Crit Care. 2011
Mar 8. 15(2):R91. [Medline].
7. Peek GJ, Elbourne D, Mugford M, Tiruvoipati R, Wilson A, Allen E, et al. Randomised controlled trial and parallel economic
evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure
(CESAR). Health Technol Assess. 2010 Jul. 14(35):1-46. [Medline].
8. Talmor D, Sarge T, Malhotra A, O'Donnell CR, Ritz R, Lisbon A, et al. Mechanical ventilation guided by esophageal pressure in
acute lung injury. N Engl J Med. 2008 Nov 13. 359 (20):2095-104. [Medline].
9. Girault C, Briel A, Benichou J, Hellot MF, Dachraoui F, Tamion F, et al. Interface strategy during noninvasive positive pressure
ventilation for hypercapnic acute respiratory failure. Crit Care Med. 2009 Jan. 37(1):124-31. [Medline].
10. Briel M, Meade M, Mercat A, Brower RG, Talmor D, Walter SD, et al. Higher vs lower positive end-expiratory pressure in
patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA. 2010 Mar
3. 303(9):865-73. [Medline].
11. Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoenfeld DA, et al. Driving pressure and survival in the acute
respiratory distress syndrome. N Engl J Med. 2015 Feb 19. 372 (8):747-55. [Medline].
12. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary
disease. N Engl J Med. 1995 Sep 28. 333(13):817-22. [Medline].
13. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary
disease on general respiratory wards: a multicentre randomised controlled trial. Lancet. 2000 Jun 3. 355(9219):1931-5.
[Medline].
14. Vitacca M, Clini E, Rubini F, Nava S, Foglio K, Ambrosino N. Non-invasive mechanical ventilation in severe chronic obstructive
lung disease and acute respiratory failure: short- and long-term prognosis. Intensive Care Med. 1996 Feb. 22(2):94-100.
[Medline].
15. Confalonieri M, Potena A, Carbone G, Porta RD, Tolley EA, Umberto Meduri G. Acute respiratory failure in patients with severe
community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med.
1999 Nov. 160(5 Pt 1):1585-91. [Medline].
16. Antonelli M, Conti G, Rocco M, et al. A comparison of noninvasive positive-pressure ventilation and conventional mechanical
ventilation in patients with acute respiratory failure. N Engl J Med. 1998 Aug 13. 339(7):429-35. [Medline].
17. [Guideline] Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official ERS/ATS clinical practice guidelines:
noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017 Aug. 50 (2):[Medline]. [Full Text].

Kaynar2018 Medscape PDF

Uploaded by

Copyright:

Available Formats

Kaynar2018 Medscape PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Kaynar2018 Medscape PDF

Uploaded by

Copyright:

Available Formats

19/10/2019 https://emedicine.medscape.

The act of respiration engages the following three processes:

Transfer of oxygen across the alveolus

Transport of oxygen to the tissues

PAO2 = FiO2 × (PB – PH2 O) – PACO2/R

Hypoxemic respiratory failure

QS/QT = (CCO2 – CaO2)/CCO2 – CvO2)

Hypercapnic respiratory failure

PaCO2 = VCO2 × K/VA

Common causes of type I (hypoxemic) respiratory failure include the following:

Pulmonary arterial hypertension

Granulomatous lung diseases

Cyanotic congenital heart disease

Acute respiratory distress syndrome (ARDS)

Fat embolism syndrome

Common causes of type II (hypercapnic) respiratory failure include the following:

Primary muscle disorders

Head and cervical cord injury

Primary alveolar hypoventilation

Criteria for the diagnosis of ARDS include the following:

Clinical presentation - Tachypnea and dyspnea; crackles upon auscultation

Radiologic appearance - 3-quadrant or 4-quadrant alveolar flooding

Lung mechanics - Diminished compliance (< 40 mL/cm water)

Aspiration Pneumonitis and Pneumonia

Cardiogenic Pulmonary Edema

Community-Acquired Pneumonia (CAP)

Idiopathic Pulmonary Fibrosis (IPF)

Interstitial (Nonidiopathic) Pulmonary Fibrosis

Neurogenic Pulmonary Edema

Obstructive Sleep Apnea (OSA)

Idiopathic Pulmonary Arterial Hypertension

Pulmonary Embolism (PE)

Restrictive Lung Disease

Pulmonary Arterial Hypertension

Pulmonary Function Tests

See Pulmonary Function Testing for further details.

Right-Sided Heart Catheterization

Principles of Mechanical Ventilation

Types of mechanical ventilation

Positive-pressure versus negative-pressure ventilation

Controlled versus patient-initiated ventilation

Pressure-targeted versus volume-targeted ventilation

Positive end-expiratory pressure

Ventilator-associated lung injury

Mechanical ventilation is associated with a variety of insults to the lung.

Ventilation Approaches for Specific Diseases

Acute respiratory distress syndrome

Obstructive airway diseases

Sometimes, additional sedation may be necessary to achieve adequate patient-ventilator synchrony.

Noninvasive Ventilatory Support

Weaning From Ventilator

Bilevel NIV is recommended as follows[17] :

Early NIV is suggested for immunocompromised patients with ARF.[17]

NIV use is suggested as follows[17] :

For patients with postoperative ARF

Nitroglycerin sublingual (Nitro-Bid, NitroMist, Nitrostat, Nitrolingual)

Nitroprusside sodium (Nitropress)

Morphine sulfate (Duramorph, Astramorph)

Terbutaline (Brethaire, Bricanyl)